设计,合成和探索周期性伊米德作为牛皮的PDE4抑制剂
Veena K S1, Pallabi Panja2, Tirtha Nath1
1Department of Medicinal Chemistry, National Institute of Pharmaceutical Education and Research (NIPER) Guwahati 781101 Assam India kalyansethi@gmail.com.
RSC medicinal chemistry
|March 4, 2026
概括
新的循环伊米德衍生物通过抑制二酶4B (PDE4B) 来治疗牛皮有希望. 化合物2k表现出显著的抗炎作用和有利的结合,使其成为潜在的治疗候选者.
科学领域:
- 药用化学 医学化学
- 药理学 药理学是指药理学的学科.
- 计算化学计算化学
背景情况:
- 牛皮是一种慢性炎症性皮肤病,口服治疗选择有限.
- 二酶4B (PDE4B) 是一种关键的炎症调节剂,也是一个有前途的治疗点.
- 选择性PDE4B抑制可能比非选择性抑制剂提供更好的安全性.
研究的目的:
- 设计,合成和评估基于周期性伊米德的新型化合物作为选择性PDE4B抑制剂.
- 评估化合物的抗炎潜力.
- 阐明强效抑制剂与PDE4B的结合机制和分子相互作用.
主要方法:
- 合成二十种周期性伊米德衍生物.
- 在体外评估PDE4B抑制活性和TNF-α抑制.
- 分子对接,DFT计算,分子动力学 (MD) 模拟和结合自由能分析.
主要成果:
- 化合物1a,2g和2k显示显著的PDE4B抑制 (>50%在1μM) 与低IC50值 (0.493,3.997和0.226μM,分别).
- 化合物2k通过抑制TNF-α诱导 (IC50 = 3.39μM) 显示出强大的抗炎活性.
- 分子建模揭示了化合物2k与PDE4B活性部位残留物和金属离子的特定相互作用,与PDE4D相比具有增强的结合稳定性.
结论:
- 化合物2k是一种非常有前途的PDE4B抑制剂,具有显著的抗炎性质.
- 详细的分子洞察力支持化合物2k作为牛皮的治疗剂的潜力.
- 需要在牛皮模型中对化合物2k进行进一步的临床前评估.
相关概念视频
Drug Discovery: Overview
10.4K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
10.4K
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
823
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
823
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
613
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
613
Structure-Activity Relationships and Drug Design
1.9K
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
1.9K


